Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

Michael Millward, T Price, A Townsend, C Sweeney, A Spencer, S Sukumaran, A Longenecker, L Lee, A Lay, G Sharma, R.M Gemmill, H.A Drabkin, G.K Lloyd, S.T.C Neuteboom, D.J Mcconkey, M.A Palladino, M.A Spear

    Research output: Contribution to journalArticlepeer-review

    113 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)2303–2317
    JournalInvestigational New Drugs
    Volume30
    DOIs
    Publication statusPublished - 2012

    Cite this